Eli Lilly and Company $LLY Stock Position Reduced by Channel Wealth LLC

Channel Wealth LLC reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 4.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,678 shares of the company’s stock after selling 465 shares during the period. Eli Lilly and Company comprises 2.7% of Channel Wealth LLC’s holdings, making the stock its 9th biggest position. Channel Wealth LLC’s holdings in Eli Lilly and Company were worth $12,355,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vista Capital Partners Inc. acquired a new stake in shares of Eli Lilly and Company in the third quarter worth $1,276,000. McElhenny Sheffield Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 8.3% during the third quarter. McElhenny Sheffield Capital Management LLC now owns 469 shares of the company’s stock worth $543,000 after purchasing an additional 36 shares during the last quarter. BankPlus Trust Department lifted its position in Eli Lilly and Company by 3.7% during the third quarter. BankPlus Trust Department now owns 6,025 shares of the company’s stock valued at $6,971,000 after purchasing an additional 216 shares during the period. Aberdeen Group plc lifted its position in Eli Lilly and Company by 1.9% during the third quarter. Aberdeen Group plc now owns 695,689 shares of the company’s stock valued at $804,968,000 after purchasing an additional 12,871 shares during the period. Finally, EagleClaw Capital Managment LLC lifted its position in Eli Lilly and Company by 3.7% during the third quarter. EagleClaw Capital Managment LLC now owns 1,837 shares of the company’s stock valued at $2,126,000 after purchasing an additional 65 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $1,444.05 on Friday. The company’s fifty day moving average price is $1,242.25 and its 200 day moving average price is $1,110.30. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,460.00. The company has a market capitalization of $1.36 trillion, a PE ratio of 46.87, a price-to-earnings-growth ratio of 1.71 and a beta of 0.40. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. During the same quarter last year, the business earned $7.02 earnings per share. The firm’s revenue was up 38.6% on a year-over-year basis. On average, research analysts predict that Eli Lilly and Company will post 35.70 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is presently 22.46%.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Guggenheim increased their price target on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research report on Friday, September 18th. UBS Group boosted their price objective on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a “buy” rating in a report on Friday, October 30th. Royal Bank Of Canada boosted their price objective on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an “outperform” rating in a report on Friday, October 30th. Bank of America reaffirmed a “buy” rating and set a $1,497.00 target price on shares of Eli Lilly and Company in a report on Friday, October 30th. Finally, Weiss Ratings lowered Eli Lilly and Company from a “buy (b+)” rating to a “buy (b)” rating in a report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,416.64.

Key Headlines Impacting Eli Lilly and Company

Investors following LLY have been watching these headlines:

• Positive Sentiment: Lilly broke ground on a $3.5 billion Pennsylvania manufacturing facility intended to make next-generation obesity medicines, including investigational retatrutide. The project supports the company’s broader production expansion, although the site is not expected to begin operations until 2031. Lilly announces Pennsylvania manufacturing facility
• Positive Sentiment: Hims & Hers will offer Lilly’s FDA-approved Zepbound and Foundayo, potentially extending patient reach through another care platform. Separately, exchange-traded funds were reported to have added to their Lilly holdings, signaling investor demand. Hims partners with Lilly to offer weight-loss drugs
• Negative Sentiment: China Merchants Securities downgraded Lilly from “buy” to “hold,” providing a cautionary view amid the positive product and capacity news. China Merchants Securities stock recommendations

Insider Activity

In other news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the transaction, the executive vice president owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.